Co-Diagnostics Inc. (CODX)
0.35
0.01 (3.86%)
At close: Apr 17, 2025, 3:58 PM
3.86% (1D)
| Bid | 0.32 |
| Market Cap | 11.66M |
| Revenue (ttm) | 1.2M |
| Net Income (ttm) | -37.64M |
| EPS (ttm) | -1.24 |
| PE Ratio (ttm) | -0.28 |
| Forward PE | 3.47 |
| Analyst | Hold |
| Ask | 0.38 |
| Volume | 21,325 |
| Avg. Volume (20D) | 191,551 |
| Open | 0.35 |
| Previous Close | 0.34 |
| Day's Range | 0.32 - 0.36 |
| 52-Week Range | 0.28 - 2.23 |
| Beta | 1.21 |
About CODX
Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. It offers polymerase chain reaction (PCR) diagnostic tests for COVID-19, tuberculosis, hepatitis B and C, human papilloma virus, malaria, chikungunya, dengue, and the zika virus; three multiplexed tests to ...
Industry Medical - Devices
Sector Healthcare
IPO Date Jul 12, 2017
Employees 132
Stock Exchange NASDAQ
Ticker Symbol CODX
Website https://www.codiagnostics.com
Analyst Forecast
According to 1 analyst ratings, the average rating for CODX stock is "Hold." The 12-month stock price forecast is $1, which is an increase of 187.85% from the latest price.
Stock ForecastsNext Earnings Release
Co-Diagnostics Inc. is scheduled to release its earnings on May 8, 2025,
during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
7 months ago
+7.2%
Co-Diagnostics shares are trading higher after the...
Unlock content with
Pro Subscription
7 months ago
+12.9%
Co-Diagnostics shares are trading higher after the CDC announced free at home Covid 19 test delivery programs will reopen in late September.
